Novel combination gene therapy pioneered at
St. Jude cures "bubble boy" disease and provides template for treating other genetic disorders. Read about the landmark study.
Collaboration will improve the understanding of how advanced technologies, such as gene therapy for hemophilia B, can move rapidly to countries with limited resources.
For the sixth consecutive year,
St. Jude has been named the Health Non-Profit Brand of the Year based on the 2019 Harris Poll EquiTrend® Equity Score.
Toxic DPRs disrupt cell function in ALS, much like uninvited dinner party guests, and displace binding partners that help maintain normal nucleolus and ribosome assembly.
Enzymes ULK1 and ULK2 play a key role in breaking down cell structures called stress granules, whose persistence leads to toxic buildup of proteins that kill muscle and brain cells
The recognition was earned for sharing several decades worth of genetic cancer data and a five-year collaboration with World Health Organization.
Explore research and resources by
St. Jude at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) in Atlanta.
This investigation draws on whole genome sequencing and other data gathered longitudinally through the
St. Jude Lifetime Cohort (SJLIFE) study.
The study identified a novel variant of the USP7 gene as playing a role in increasing the risk of developing T-ALL. The inherited genetic variant is linked to lower expression of USP7.
Research ranges on a variety of topics such as survivorship, clinical genomics, deep sequencing, disease models and the biology of pediatric cancers.
Genomic analysis reveals the biology of acute erythroid leukemia, a rare cancer with few survivors
St. Jude Cancer Control and Survivorship Program is a multidisciplinary research program which strives to improve the quality of life of individuals surviving childhood cancer.
The agreement reflects the
St. Jude commitment to transform pediatric cancer care in low- to moderate-income nations that are home to 90 percent of childhood cancer patients.
Check out what happens when math and biology combine to tackle error rates in next-generation DNA sequencing. The answer is good news for cancer patients.
Downing will discuss our understanding of the molecular landscape of childhood cancer, which can benefit cancer patients of all ages and raise global cancer cure rates.
Comprehensive clinical genomic testing proves its worth; leads to discovery of a mutation that drives the most common childhood melanoma.
Cooperative clinical trial gives immediate postoperative radiation for children under age 3 with ependymoma, illustrates effectiveness of postoperative radiation.
Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease.
The institution is the highest-ranked Memphis-based organization; for nearly a decade, Fortune has recognized the hospital’s commitment to employee
St. Jude Children’s Research Hospital announced it has been named a recipient of Microsoft Corp.’s 2019 Health Innovation Awards.
Researchers developed a method for customizing and reducing drug interaction alerts in electronic health records for pediatric cancer patients.
New program will integrate traditional training and experiential learning at
St. Jude campus and partner site.
The study reports how two unexpected partners, the proteins UTX and 53BP1, link up to regulate a brain development program comprising hundreds of genes.
Survey results should help health system leaders and patient safety experts dedicate resources to improve safety and clinical outcomes in pediatric health care.
Children with hypodiploid acute lymphoblastic leukemia fare better when minimal residual disease is used to guide treatment.
Research led by
St. Jude Children's Research Hospital means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.
Investigators studied the effects of the H3 K27M mutation, and revealed its impact on mutations that are known drivers of DIPGs.
Read about the newly identified subset of helper T 17 immune cells that suggest a novel approach for taming chronic inflammation.
Global Esports organization, Immortals, haspartnered with
St. Jude to raise $500,000 to help children battling cancer and other life-threatening diseases..
The largest one-time gift in the history of
St. Jude will fund the new Family Commons, a treatment-free floor for patients and their families.